nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—ADORA2A—NGF-independant TRKA activation—ADCYAP1—esophageal cancer	0.146	0.331	CbGpPWpGaD
Regadenoson—ADORA2A—Activation of TRKA receptors—ADCYAP1—esophageal cancer	0.126	0.286	CbGpPWpGaD
Regadenoson—Oral discomfort—Capecitabine—esophageal cancer	0.0475	0.0888	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—MMP14—esophageal cancer	0.0181	0.041	CbGpPWpGaD
Regadenoson—Pain in jaw—Capecitabine—esophageal cancer	0.0168	0.0314	CcSEcCtD
Regadenoson—Bronchial hyperreactivity—Methotrexate—esophageal cancer	0.0156	0.0292	CcSEcCtD
Regadenoson—Chronic obstructive pulmonary disease—Methotrexate—esophageal cancer	0.0143	0.0267	CcSEcCtD
Regadenoson—Altered state of consciousness—Capecitabine—esophageal cancer	0.0118	0.0222	CcSEcCtD
Regadenoson—Peripheral coldness—Capecitabine—esophageal cancer	0.0115	0.0215	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.0112	0.0254	CbGpPWpGaD
Regadenoson—Transient ischaemic attack—Capecitabine—esophageal cancer	0.0108	0.0203	CcSEcCtD
Regadenoson—Adenosine monophosphate—PDE4D—esophageal cancer	0.00995	0.414	CrCbGaD
Regadenoson—Respiratory distress—Capecitabine—esophageal cancer	0.00861	0.0161	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABL1—esophageal cancer	0.00833	0.347	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—KDR—esophageal cancer	0.00809	0.0183	CbGpPWpGaD
Regadenoson—Pain—Carboplatin—esophageal cancer	0.00772	0.0144	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—CRTC1—esophageal cancer	0.00761	0.0172	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCYAP1—esophageal cancer	0.00746	0.0169	CbGpPWpGaD
Regadenoson—Wheezing—Cisplatin—esophageal cancer	0.00721	0.0135	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—CREBBP—esophageal cancer	0.00691	0.0156	CbGpPWpGaD
Regadenoson—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00681	0.0127	CcSEcCtD
Regadenoson—Injection site pain—Capecitabine—esophageal cancer	0.0067	0.0125	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—PDE4D—esophageal cancer	0.0066	0.0149	CbGpPWpGaD
Regadenoson—Extrasystoles—Capecitabine—esophageal cancer	0.0065	0.0122	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—GNG7—esophageal cancer	0.00628	0.0142	CbGpPWpGaD
Regadenoson—Chest discomfort—Capecitabine—esophageal cancer	0.00618	0.0116	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ADCYAP1—esophageal cancer	0.00574	0.013	CbGpPWpGaD
Regadenoson—Cerebrovascular accident—Cisplatin—esophageal cancer	0.0055	0.0103	CcSEcCtD
Regadenoson—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00528	0.00988	CcSEcCtD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—EP300—esophageal cancer	0.0047	0.0107	CbGpPWpGaD
Regadenoson—Abdominal discomfort—Cisplatin—esophageal cancer	0.00446	0.00835	CcSEcCtD
Regadenoson—Eye pain—Capecitabine—esophageal cancer	0.0044	0.00823	CcSEcCtD
Regadenoson—Atrial fibrillation—Capecitabine—esophageal cancer	0.00419	0.00784	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCC2—esophageal cancer	0.00419	0.174	CrCbGaD
Regadenoson—Renal impairment—Capecitabine—esophageal cancer	0.00417	0.00781	CcSEcCtD
Regadenoson—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00409	0.00766	CcSEcCtD
Regadenoson—Renal failure—Cisplatin—esophageal cancer	0.00408	0.00763	CcSEcCtD
Regadenoson—Myocardial infarction—Cisplatin—esophageal cancer	0.00407	0.00761	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00406	0.00921	CbGpPWpGaD
Regadenoson—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00405	0.00758	CcSEcCtD
Regadenoson—Pain in extremity—Capecitabine—esophageal cancer	0.00397	0.00743	CcSEcCtD
Regadenoson—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00393	0.00736	CcSEcCtD
Regadenoson—Bradycardia—Cisplatin—esophageal cancer	0.00379	0.0071	CcSEcCtD
Regadenoson—Cardiac arrest—Capecitabine—esophageal cancer	0.00378	0.00706	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKAP13—esophageal cancer	0.0037	0.00838	CbGpPWpGaD
Regadenoson—Connective tissue disorder—Cisplatin—esophageal cancer	0.00366	0.00685	CcSEcCtD
Regadenoson—Eye disorder—Cisplatin—esophageal cancer	0.00348	0.00651	CcSEcCtD
Regadenoson—Tinnitus—Cisplatin—esophageal cancer	0.00347	0.0065	CcSEcCtD
Regadenoson—Cardiac disorder—Cisplatin—esophageal cancer	0.00346	0.00647	CcSEcCtD
Regadenoson—Flushing—Cisplatin—esophageal cancer	0.00346	0.00647	CcSEcCtD
Regadenoson—Abdominal distension—Capecitabine—esophageal cancer	0.00346	0.00646	CcSEcCtD
Regadenoson—Asthma—Capecitabine—esophageal cancer	0.00343	0.00642	CcSEcCtD
Regadenoson—Bronchospasm—Capecitabine—esophageal cancer	0.00338	0.00632	CcSEcCtD
Regadenoson—Immune system disorder—Cisplatin—esophageal cancer	0.00337	0.0063	CcSEcCtD
Regadenoson—Mediastinal disorder—Cisplatin—esophageal cancer	0.00336	0.00628	CcSEcCtD
Regadenoson—Angina pectoris—Capecitabine—esophageal cancer	0.00334	0.00625	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—GHRL—esophageal cancer	0.00331	0.0075	CbGpPWpGaD
Regadenoson—Abdominal discomfort—Capecitabine—esophageal cancer	0.00329	0.00615	CcSEcCtD
Regadenoson—Erythema—Cisplatin—esophageal cancer	0.00324	0.00607	CcSEcCtD
Regadenoson—Vision blurred—Cisplatin—esophageal cancer	0.00306	0.00572	CcSEcCtD
Regadenoson—Tremor—Cisplatin—esophageal cancer	0.00304	0.00569	CcSEcCtD
Regadenoson—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00302	0.00564	CcSEcCtD
Regadenoson—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00302	0.00564	CcSEcCtD
Regadenoson—Ill-defined disorder—Cisplatin—esophageal cancer	0.00301	0.00563	CcSEcCtD
Regadenoson—Renal failure—Capecitabine—esophageal cancer	0.00301	0.00563	CcSEcCtD
Regadenoson—Myocardial infarction—Capecitabine—esophageal cancer	0.003	0.00561	CcSEcCtD
Regadenoson—Malaise—Cisplatin—esophageal cancer	0.00293	0.00547	CcSEcCtD
Regadenoson—Convulsion—Cisplatin—esophageal cancer	0.00281	0.00526	CcSEcCtD
Regadenoson—Bradycardia—Capecitabine—esophageal cancer	0.0028	0.00523	CcSEcCtD
Regadenoson—Myalgia—Cisplatin—esophageal cancer	0.00276	0.00517	CcSEcCtD
Regadenoson—Anxiety—Cisplatin—esophageal cancer	0.00275	0.00515	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00274	0.00513	CcSEcCtD
Regadenoson—Hypoaesthesia—Capecitabine—esophageal cancer	0.00273	0.00511	CcSEcCtD
Regadenoson—Discomfort—Cisplatin—esophageal cancer	0.00273	0.0051	CcSEcCtD
Regadenoson—Connective tissue disorder—Capecitabine—esophageal cancer	0.0027	0.00505	CcSEcCtD
Regadenoson—Anaphylactic shock—Cisplatin—esophageal cancer	0.00265	0.00495	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00264	0.00597	CbGpPWpGaD
Regadenoson—Nervous system disorder—Cisplatin—esophageal cancer	0.0026	0.00486	CcSEcCtD
Regadenoson—Tachycardia—Cisplatin—esophageal cancer	0.00258	0.00483	CcSEcCtD
Regadenoson—Skin disorder—Cisplatin—esophageal cancer	0.00257	0.00481	CcSEcCtD
Regadenoson—Eye disorder—Capecitabine—esophageal cancer	0.00257	0.0048	CcSEcCtD
Regadenoson—Tinnitus—Capecitabine—esophageal cancer	0.00256	0.00479	CcSEcCtD
Regadenoson—Hyperhidrosis—Cisplatin—esophageal cancer	0.00256	0.00479	CcSEcCtD
Regadenoson—Asthma—Methotrexate—esophageal cancer	0.00256	0.00478	CcSEcCtD
Regadenoson—Cardiac disorder—Capecitabine—esophageal cancer	0.00255	0.00477	CcSEcCtD
Regadenoson—Flushing—Capecitabine—esophageal cancer	0.00255	0.00477	CcSEcCtD
Regadenoson—Angiopathy—Capecitabine—esophageal cancer	0.00249	0.00466	CcSEcCtD
Regadenoson—Immune system disorder—Capecitabine—esophageal cancer	0.00248	0.00464	CcSEcCtD
Regadenoson—Mediastinal disorder—Capecitabine—esophageal cancer	0.00248	0.00463	CcSEcCtD
Regadenoson—Hypotension—Cisplatin—esophageal cancer	0.00247	0.00463	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00245	0.00555	CbGpPWpGaD
Regadenoson—Abdominal discomfort—Methotrexate—esophageal cancer	0.00245	0.00458	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00241	0.00451	CcSEcCtD
Regadenoson—Mental disorder—Capecitabine—esophageal cancer	0.00241	0.0045	CcSEcCtD
Regadenoson—Erythema—Capecitabine—esophageal cancer	0.00239	0.00447	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00238	0.0054	CbGpPWpGaD
Regadenoson—Paraesthesia—Cisplatin—esophageal cancer	0.00238	0.00445	CcSEcCtD
Regadenoson—Dyspnoea—Cisplatin—esophageal cancer	0.00236	0.00442	CcSEcCtD
Regadenoson—Dysgeusia—Capecitabine—esophageal cancer	0.00234	0.00438	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00232	0.00526	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.0023	0.0052	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00229	0.00428	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GNG7—esophageal cancer	0.00228	0.00516	CbGpPWpGaD
Regadenoson—Pain—Cisplatin—esophageal cancer	0.00226	0.00424	CcSEcCtD
Regadenoson—Vision blurred—Capecitabine—esophageal cancer	0.00225	0.00422	CcSEcCtD
Regadenoson—Tremor—Capecitabine—esophageal cancer	0.00224	0.00419	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—esophageal cancer	0.00224	0.00419	CcSEcCtD
Regadenoson—Ill-defined disorder—Capecitabine—esophageal cancer	0.00222	0.00415	CcSEcCtD
Regadenoson—Feeling abnormal—Cisplatin—esophageal cancer	0.00218	0.00408	CcSEcCtD
Regadenoson—Malaise—Capecitabine—esophageal cancer	0.00216	0.00403	CcSEcCtD
Regadenoson—Syncope—Capecitabine—esophageal cancer	0.00214	0.00401	CcSEcCtD
Regadenoson—Palpitations—Capecitabine—esophageal cancer	0.00211	0.00395	CcSEcCtD
Regadenoson—Loss of consciousness—Capecitabine—esophageal cancer	0.0021	0.00393	CcSEcCtD
Regadenoson—Cough—Capecitabine—esophageal cancer	0.00209	0.0039	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00209	0.00473	CbGpPWpGaD
Regadenoson—Hypertension—Capecitabine—esophageal cancer	0.00206	0.00386	CcSEcCtD
Regadenoson—Arthralgia—Capecitabine—esophageal cancer	0.00204	0.00381	CcSEcCtD
Regadenoson—Chest pain—Capecitabine—esophageal cancer	0.00204	0.00381	CcSEcCtD
Regadenoson—Myalgia—Capecitabine—esophageal cancer	0.00204	0.00381	CcSEcCtD
Regadenoson—Anxiety—Capecitabine—esophageal cancer	0.00203	0.0038	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00202	0.00378	CcSEcCtD
Regadenoson—Discomfort—Capecitabine—esophageal cancer	0.00201	0.00376	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL2—esophageal cancer	0.00201	0.00455	CbGpPWpGaD
Regadenoson—Hypersensitivity—Cisplatin—esophageal cancer	0.00195	0.00365	CcSEcCtD
Regadenoson—Shock—Capecitabine—esophageal cancer	0.00192	0.00359	CcSEcCtD
Regadenoson—Nervous system disorder—Capecitabine—esophageal cancer	0.00191	0.00358	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GDI2—esophageal cancer	0.00191	0.00433	CbGpPWpGaD
Regadenoson—Eye disorder—Methotrexate—esophageal cancer	0.00191	0.00358	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—esophageal cancer	0.00191	0.00357	CcSEcCtD
Regadenoson—Tachycardia—Capecitabine—esophageal cancer	0.0019	0.00356	CcSEcCtD
Regadenoson—Asthenia—Cisplatin—esophageal cancer	0.0019	0.00355	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—esophageal cancer	0.0019	0.00355	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—esophageal cancer	0.0019	0.00355	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—esophageal cancer	0.00189	0.00353	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ANXA1—esophageal cancer	0.00187	0.00423	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NOS2—esophageal cancer	0.00186	0.00421	CbGpPWpGaD
Regadenoson—Angiopathy—Methotrexate—esophageal cancer	0.00186	0.00347	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—esophageal cancer	0.00185	0.00346	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—esophageal cancer	0.00184	0.00345	CcSEcCtD
Regadenoson—Hypotension—Capecitabine—esophageal cancer	0.00182	0.00341	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—SST—esophageal cancer	0.00182	0.00411	CbGpPWpGaD
Regadenoson—Diarrhoea—Cisplatin—esophageal cancer	0.00181	0.00339	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—esophageal cancer	0.00179	0.00335	CcSEcCtD
Regadenoson—Erythema—Methotrexate—esophageal cancer	0.00178	0.00333	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00178	0.00333	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GHRL—esophageal cancer	0.00177	0.00401	CbGpPWpGaD
Regadenoson—Insomnia—Capecitabine—esophageal cancer	0.00177	0.0033	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—esophageal cancer	0.00175	0.00328	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—esophageal cancer	0.00174	0.00326	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—esophageal cancer	0.00174	0.00325	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00169	0.00315	CcSEcCtD
Regadenoson—Vomiting—Cisplatin—esophageal cancer	0.00168	0.00315	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—esophageal cancer	0.00168	0.00314	CcSEcCtD
Regadenoson—Rash—Cisplatin—esophageal cancer	0.00167	0.00312	CcSEcCtD
Regadenoson—Pain—Capecitabine—esophageal cancer	0.00167	0.00312	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—esophageal cancer	0.00167	0.00312	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—esophageal cancer	0.00165	0.00309	CcSEcCtD
Regadenoson—Feeling abnormal—Capecitabine—esophageal cancer	0.00161	0.00301	CcSEcCtD
Regadenoson—Malaise—Methotrexate—esophageal cancer	0.00161	0.003	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0016	0.00299	CcSEcCtD
Regadenoson—Nausea—Cisplatin—esophageal cancer	0.00157	0.00294	CcSEcCtD
Regadenoson—Cough—Methotrexate—esophageal cancer	0.00155	0.00291	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—esophageal cancer	0.00155	0.0029	CcSEcCtD
Regadenoson—Abdominal pain—Capecitabine—esophageal cancer	0.00154	0.00289	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—esophageal cancer	0.00154	0.00289	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—esophageal cancer	0.00154	0.0642	CrCbGaD
Regadenoson—Myalgia—Methotrexate—esophageal cancer	0.00152	0.00284	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—esophageal cancer	0.00152	0.00284	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—esophageal cancer	0.00152	0.00284	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00151	0.00282	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—esophageal cancer	0.0015	0.0028	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.00148	0.00335	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Methotrexate—esophageal cancer	0.00145	0.00272	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—esophageal cancer	0.00144	0.00269	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—esophageal cancer	0.00142	0.00267	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—esophageal cancer	0.00141	0.00264	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—esophageal cancer	0.0014	0.00263	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—esophageal cancer	0.0014	0.00262	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—KMT2D—esophageal cancer	0.00138	0.00313	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—esophageal cancer	0.00137	0.0031	CbGpPWpGaD
Regadenoson—Hypotension—Methotrexate—esophageal cancer	0.00136	0.00254	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.00135	0.00307	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKAP13—esophageal cancer	0.00134	0.00305	CbGpPWpGaD
Regadenoson—Diarrhoea—Capecitabine—esophageal cancer	0.00134	0.0025	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00132	0.00248	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—esophageal cancer	0.00131	0.00246	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—esophageal cancer	0.0013	0.00244	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—esophageal cancer	0.0013	0.00242	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—esophageal cancer	0.00129	0.00242	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—esophageal cancer	0.00129	0.00241	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GNG7—esophageal cancer	0.00129	0.00292	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00125	0.00235	CcSEcCtD
Regadenoson—Pain—Methotrexate—esophageal cancer	0.00124	0.00232	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—esophageal cancer	0.00124	0.00232	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.00123	0.00279	CbGpPWpGaD
Regadenoson—Rash—Capecitabine—esophageal cancer	0.00123	0.0023	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—esophageal cancer	0.00123	0.0023	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PDE4D—esophageal cancer	0.00123	0.00279	CbGpPWpGaD
Regadenoson—Headache—Capecitabine—esophageal cancer	0.00122	0.00229	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—esophageal cancer	0.0012	0.00224	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00119	0.00222	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—esophageal cancer	0.00117	0.00265	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNG7—esophageal cancer	0.00117	0.00265	CbGpPWpGaD
Regadenoson—Nausea—Capecitabine—esophageal cancer	0.00116	0.00217	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—esophageal cancer	0.00115	0.00216	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—esophageal cancer	0.00115	0.00215	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—EP300—esophageal cancer	0.00114	0.00257	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.00113	0.00257	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WWOX—esophageal cancer	0.00113	0.00255	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FKBP1A—esophageal cancer	0.00107	0.00243	CbGpPWpGaD
Regadenoson—Hypersensitivity—Methotrexate—esophageal cancer	0.00107	0.002	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.00105	0.00239	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—esophageal cancer	0.00105	0.00238	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WIF1—esophageal cancer	0.00105	0.00237	CbGpPWpGaD
Regadenoson—Asthenia—Methotrexate—esophageal cancer	0.00104	0.00195	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL2—esophageal cancer	0.00103	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—SST—esophageal cancer	0.00103	0.00232	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GHRL—esophageal cancer	0.001	0.00227	CbGpPWpGaD
Regadenoson—Diarrhoea—Methotrexate—esophageal cancer	0.000994	0.00186	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000967	0.00219	CbGpPWpGaD
Regadenoson—Dizziness—Methotrexate—esophageal cancer	0.000961	0.0018	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000958	0.00217	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—esophageal cancer	0.000949	0.00215	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SST—esophageal cancer	0.000932	0.00211	CbGpPWpGaD
Regadenoson—Vomiting—Methotrexate—esophageal cancer	0.000924	0.00173	CcSEcCtD
Regadenoson—Rash—Methotrexate—esophageal cancer	0.000916	0.00171	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—esophageal cancer	0.000915	0.00171	CcSEcCtD
Regadenoson—Headache—Methotrexate—esophageal cancer	0.00091	0.0017	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GHRL—esophageal cancer	0.000908	0.00206	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PFN1—esophageal cancer	0.000904	0.00205	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—esophageal cancer	0.0009	0.00204	CbGpPWpGaD
Regadenoson—Nausea—Methotrexate—esophageal cancer	0.000863	0.00161	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—esophageal cancer	0.000823	0.00187	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ELMO1—esophageal cancer	0.000812	0.00184	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—esophageal cancer	0.000812	0.00184	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKAP13—esophageal cancer	0.000794	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000733	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—esophageal cancer	0.00073	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE4D—esophageal cancer	0.000726	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNG7—esophageal cancer	0.000691	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—XIAP—esophageal cancer	0.000647	0.00147	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—esophageal cancer	0.000633	0.00143	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000612	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL2—esophageal cancer	0.000609	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSME1—esophageal cancer	0.000568	0.00129	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSME2—esophageal cancer	0.000568	0.00129	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ANXA1—esophageal cancer	0.000566	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SST—esophageal cancer	0.00055	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH3—esophageal cancer	0.000536	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHRL—esophageal cancer	0.000536	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FBXW7—esophageal cancer	0.000528	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH2—esophageal cancer	0.000481	0.00109	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFBR2—esophageal cancer	0.000427	0.000967	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SMAD4—esophageal cancer	0.000404	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—esophageal cancer	0.000331	0.000749	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—esophageal cancer	0.000316	0.000716	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH1—esophageal cancer	0.000298	0.000675	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CREBBP—esophageal cancer	0.00027	0.000612	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—esophageal cancer	0.000265	0.000601	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000254	0.000574	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—esophageal cancer	0.000242	0.000548	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—esophageal cancer	0.00023	0.000522	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—esophageal cancer	0.000226	0.000512	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—esophageal cancer	0.0002	0.000453	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—esophageal cancer	0.000193	0.000438	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EP300—esophageal cancer	0.000184	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—esophageal cancer	0.00016	0.000363	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—esophageal cancer	0.000157	0.000355	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—esophageal cancer	0.000136	0.000308	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—esophageal cancer	0.000132	0.000298	CbGpPWpGaD
